Jefferies Group Analysts Raise Earnings Estimates for Antares Pharma, Inc. (ATRS)
Antares Pharma, Inc. (NASDAQ:ATRS) – Jefferies Group increased their FY2019 earnings per share estimates for shares of Antares Pharma in a report issued on Tuesday. Jefferies Group analyst A. Petrone now forecasts that the specialty pharmaceutical company will post earnings of $0.05 per share for the year, up from their previous forecast of $0.04. Jefferies Group also issued estimates for Antares Pharma’s FY2020 earnings at $0.21 EPS.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 40.24% and a negative net margin of 34.27%. The firm had revenue of $13.42 million for the quarter, compared to the consensus estimate of $12.99 million.
Other equities analysts have also recently issued research reports about the company. Vetr upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target on the stock in a research report on Wednesday, July 5th. Chardan Capital started coverage on Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a research report on Friday, June 23rd. Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, Raymond James Financial, Inc. started coverage on Antares Pharma in a research report on Thursday, April 20th. They issued a “strong-buy” rating and a $4.30 price target on the stock. One analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $3.83.
Shares of Antares Pharma (ATRS) traded down 2.00% during mid-day trading on Thursday, hitting $2.94. The stock had a trading volume of 813,678 shares. The firm has a 50 day moving average price of $3.15 and a 200 day moving average price of $2.76. Antares Pharma has a 52-week low of $1.01 and a 52-week high of $3.37. The firm’s market cap is $458.42 million.
In related news, insider Fred M. Powell purchased 130,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were purchased at an average price of $2.79 per share, for a total transaction of $362,700.00. Following the transaction, the insider now directly owns 331,434 shares of the company’s stock, valued at approximately $924,700.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.60% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Alliancebernstein L.P. bought a new position in shares of Antares Pharma during the second quarter valued at about $119,000. Legal & General Group Plc bought a new position in shares of Antares Pharma during the second quarter valued at about $120,000. Credit Suisse AG bought a new position in shares of Antares Pharma during the first quarter valued at about $146,000. National Planning Corp boosted its position in shares of Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares during the period. Finally, KCG Holdings Inc. boosted its position in shares of Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares during the period. Hedge funds and other institutional investors own 31.70% of the company’s stock.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.